Compare DexCom, Inc. (DXCM) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ProShares UltraPro QQQ ETF — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while ProShares UltraPro QQQ ETF trades at $81.35 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is the larger of the two by market cap, and ProShares UltraPro QQQ ETF is more actively traded (65,384,797 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| DXCM | TQQQ | |
|---|---|---|
Market Cap | $31.86B | $38.74B |
Volume | 3,607,070 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.34 | $87.22 |
52-Week Low | $54.84 | $37.89 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
TQQQ trades at $81.16, down 2.92% on the day, with technical indicators showing a bullish overall signal despite recent selling pressure. The leveraged ETF structure amplifies both gains and losses, with recent news highlighting hidden costs beyond the stated 0.82% expense ratio. Support levels are established at $78 and $76, while resistance sits at $83 and $85.
The outlook for TQQQ remains tied to Nasdaq-100 performance and tech sector momentum, though volatility decay and financing costs present significant long-term risks. Current technical positioning suggests potential for near-term upside if support holds, but investors should be cautious of amplified losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
